Conversations on Cancer: Strength in Numbers, Increasing Cancer Awareness while Decreasing Disparities
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discusses an exploratory analysis from the FLAURA2 study, which indicates that baseline levels of plasma EGFR…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The 64th Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 28-30 April 2024 in Liverpool, UK, and brought together hematology…
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal…
Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.
Cabozantinib shows promising activity in patients with MPPGs.
Application deadline: 31 May 2024 (12:00 CEST)
In a French noncomparative phase II trial, investigators established limited activity of FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus durvalumab or durvalumab/tremelimumab in the second-lin…
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Notice of Special Interest (NOSI): Administrative Supplement to Support the NCI Cancer…
HSC increase autophagy in response to mitochondrial stress and cytokine stimulation with IL-1β and TNF identified as key inducers.HSC and HPC require autop